Literature DB >> 18715151

Apurinic/apyrimidinic endonuclease/redox effector factor-1(APE/Ref-1): a unique target for the prevention and treatment of human melanoma.

Sun Yang1, Frank L Meyskens.   

Abstract

Management of melanoma is a growing and challenging public health issue requiring novel and multidisciplinary approaches to achieve more efficient prevention and therapeutic benefits. The aim of this article is to show the critical role of APE/Ref-1 on melanomagenesis and progression. APE/Ref-1 serves as a redox-sensitive node of convergence of various signals as well as a DNA-repair enzyme, and its activation protects melanocytes and melanoma cells from chronic oxidative stress and promotes cell survival via mediation of downstream pathways. APE/Ref-1 is a strong candidate as a potential drug-treatable target for the prevention and treatment of human melanoma. Lead compounds exhibiting inhibitory effects on APE/Ref-1 are also reviewed. We anticipate potential clinical benefit in the future through inhibition of APE/Ref-1 and/or Ref-1-mediated signaling.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 18715151      PMCID： PMC2933576          DOI： 10.1089/ars.2008.2226

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN： 1523-0864            Impact factor:   8.401


  124 in total

1.  Redox regulation of the DNA repair function of the human AP endonuclease Ape1/ref-1.

Authors:  M R Kelley; S H Parsons
Journal:  Antioxid Redox Signal       Date:  2001-08       Impact factor: 8.401

2.  Addition of iron and zinc complexes to Eagle's Minimal Essential Medium is sufficient to induce and support the proliferation of B16 melanoma cells.

Authors:  W Korohoda; M Michalik; Z Pietzkowski; E Zaporowska-Siwiak
Journal:  Folia Histochem Cytobiol       Date:  1993       Impact factor: 1.698

3.  HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.

Authors:  Michael J Gray; Jing Zhang; Lee M Ellis; Gregg L Semenza; Douglas B Evans; Stephanie S Watowich; Gary E Gallick
Journal:  Oncogene       Date:  2005-04-28       Impact factor: 9.867

Review 4.  Cancer incidence and causes of death among total hip replacement patients: a review based on Nordic cohorts with a special emphasis on metal-on-metal bearings.

Authors:  T I Visuri; E Pukkala; P Pulkkinen; P Paavolainen
Journal:  Proc Inst Mech Eng H       Date:  2006-02       Impact factor: 1.617

5.  Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer.

Authors:  Alessandro M Minisini; Carla Di Loreto; Mauro Mansutti; Daria Artico; Stefano Pizzolitto; Andrea Piga; Fabio Puglisi
Journal:  Cancer Lett       Date:  2004-12-13       Impact factor: 8.679

6.  Abasic sites in DNA of HeLa cells induced by lucanthone.

Authors:  Frances Mendez; Joshua D Goldman; Robert E Bases
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

7.  Jun D cooperates with p65 to activate the proximal kappaB site of the cyclin D1 promoter: role of PI3K/PDK-1.

Authors:  Kahina Toualbi-Abed; Fanny Daniel; Meryem C Güller; Agnès Legrand; Jose-Luis Mauriz; Alain Mauviel; Dominique Bernuau
Journal:  Carcinogenesis       Date:  2008-01-03       Impact factor: 4.944

8.  Topical applications of iron chelators in photosensitization.

Authors:  Asta Juzeniene; Petras Juzenas; Vladimir Iani; Johan Moan
Journal:  Photochem Photobiol Sci       Date:  2007-09-11       Impact factor: 3.982

Review 9.  Let the sun shine in: mechanisms and potential for therapeutics in skin photodamage.

Authors:  Georg T Wondrak
Journal:  Curr Opin Investig Drugs       Date:  2007-05

10.  Inhibition of Ape1 nuclease activity by lead, iron, and cadmium.

Authors:  Daniel R McNeill; Avinash Narayana; Heng-Kuan Wong; David M Wilson
Journal:  Environ Health Perspect       Date:  2004-05       Impact factor: 9.031
View more
  9 in total

Review 1.  APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1.

Authors:  Mark R Kelley; Millie M Georgiadis; Melissa L Fishel
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

2.  Bis-Cinnamamide Derivatives as APE/Ref-1 Inhibitors for the Treatment of Human Melanoma.

Authors:  Razan Alhazmi; Shirley Tong; Shaban Darwish; Elina Khanjani; Bharti Khungar; Swati Chawla; Zhonghui Zheng; Richard Chamberlin; Keykavous Parang; Sun Yang
Journal:  Molecules       Date:  2022-04-21       Impact factor: 4.927

Review 3.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

4.  Degradation of NF-κB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells.

Authors:  Ameya Paranjpe; Kalkunte S Srivenugopal
Journal:  Carcinogenesis       Date:  2013-01-25       Impact factor: 4.944

Review 5.  Modulation of nuclear receptor function by cellular redox poise.

Authors:  Eric L Carter; Stephen W Ragsdale
Journal:  J Inorg Biochem       Date:  2014-01-21       Impact factor: 4.155

Review 6.  The Tumorigenic Roles of the Cellular REDOX Regulatory Systems.

Authors:  Stéphanie Anaís Castaldo; Joana Raquel Freitas; Nadine Vasconcelos Conchinha; Patrícia Alexandra Madureira
Journal:  Oxid Med Cell Longev       Date:  2015-11-22       Impact factor: 6.543

7.  Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.

Authors:  Ryan W Dellinger; Harry H Matundan; Amelia S Ahmed; Priscilla H Duong; Frank L Meyskens
Journal:  PLoS One       Date:  2012-10-22       Impact factor: 3.240

8.  Resistance exercise training increase activation of AKT-eNOS and Ref-1 expression by FOXO-1 activation in aorta of F344 rats.

Authors:  Meng Li; Wei Li; Jin-Hwan Yoon; Byeong Hwa Jeon; Sang Ki Lee
Journal:  J Exerc Nutrition Biochem       Date:  2015-07-31

9.  Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy.

Authors:  Rachel Abbotts; Rosalyn Jewell; Jérémie Nsengimana; David J Maloney; Anton Simeonov; Claire Seedhouse; Faye Elliott; Jon Laye; Christy Walker; Ajit Jadhav; Anna Grabowska; Graham Ball; Poulam M Patel; Julia Newton-Bishop; David M Wilson; Srinivasan Madhusudan
Journal:  Oncotarget       Date:  2014-05-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.